Milnacipran for Treatment of Fibromyalgia: A Review of Clinical Trials

Kyung Eun Lee
Boston Medical Center, One Boston Medical Center Place, Boston, MA 02118, USA

(Received October 8, 2010 · Revised October 29, 2010 · Accepted November 4, 2010)

Fibromyalgia (FM), also called fibromyalgia syndrome (FMS) is a chronic systemic disorder characterized by widespread pain in joint and muscle leading to variety of other symptoms including profound fatigue, multiple tender points, stiffness, cognitive dysfunction, sleep disturbances and decreased physical function. The presence of fibromyalgia is more common in women then in man and affects 2.2% of Korean population.1-4) Fibromyalgia is often misdiagnosed because of the difficulty of understanding the disease and nonspecific symptoms. It is unknown why fibromyalgia develops or what causes its symptoms. However, there is a hypothesis that individuals who develop fibromyalgia may have a associated genetic, biochemical and environmental conditions.5) American College of Rheumatology (ACR) established classification criteria of fibromyalgia in 1990 for the purpose of standardizing clinical trial populations. These criteria require that an individual to have chronic widespread pain in all four quadrants of the body for at least 3 months and also to present 11 of 18 standardized tender points on palpable examination.6) The pathophysiology of fibromyalgia is not well understood but increasing evidence suggests abnormalities of pain processing in central nervous system resulting in central pain sensitization.7,8) Treatment can be difficult because of unknown etiology of fibromyalgia. For such reason nonpharmacologic or complementary therapies such as exercise, massage, chiropractic, acupuncture, biofeedback therapy or cognitive behavior therapy are broadly used. Tricyclic
antidepressants (TCA) and selective serotonin reuptake inhibitors (SSRI) have been used for fibromyalgia as off labeled indication.9-10) Pregabalin is the first drug to be approved by US Food and Drug Administration (FDA) for the management of fibromyalgia in June 2007. Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) that was approved in June 2008 for the same manner. Milnacipran, another SNRI, became the third FDA approved drug for the management of fibromyalgia in January 2009.11-12) SNRIs have shown analgesic effects in animal model which suggest that these neurotransmitters are of importance in pain modulation.13-14)

Milnacipran is marketed for the treatment of major depressive disorder in over 45 countries worldwide. Milnacipran has the unique property over other dual reuptake inhibitors by its three times greater potency for norepinephrine over serotonin in vitro. It is similar to TCAs in its ability to inhibit both norepinephrine and serotonin but does not interact with muscarinic, dopaminergic, histaminergic, or α- or β-adrenergic receptors, therefore have favorable tolerability profile. Pharmacokinetically, milnacipran shows 85-90% bioavailability following oral administration which is not affected by food. Its high bioavailability is influenced by a large volume of distribution (400 L) and a weak protein binding (13%). Milnacipran is not metabolized by cytochrome P450 contributing to less possible drug-drug interactions. These kinetic properties may be beneficial in fibromyalgia patients who also have other disease conditions or have developed polypharmacy. The terminal elimination half-life of milnacipran is 6-8 hours and 55% is excreted unchanged into the urine. Patients with moderate renal impairment (estimated creatine clearance 30-49 mL/min) need close monitoring and patients with severe renal impairment (estimated creatine clearance 5-29 mL/min) require dose adjustment. Safety and efficacy of milnacipran in fibromyalgia patients under 17 years of age have not been established therefore, milnacipran is not recommended in pediatric patients.15-18)

DATA SOURCES

A comprehensive MEDLINE search was performed with no restriction on year for clinical trials published in English using the MeSH terms fibromyalgia and milnacipran. Clinical trials evaluating the efficacy and safety of milnacipran were selected and reviewed.

CLINICAL TRIALS

Evaluation of the efficacy and safety of milnacipran in the treatment of fibromyalgia has been reported in 6 randomized, double-blind trials ranging from 3 months to 1 year up to date.19-24) Participants in the studies were primarily white women between 40 and 50 years of age with 4 to 11 years of history of fibromyalgia. Inclusion and exclusion criteria were similar among the studies. Age of the patients ranged between 18 and 70 years old, except the extension trial by Goldenberg et al.,22) which included 71 years old patients. American College of Rheumatology (ACR) diagnostic criteria for fibromyalgia was used to include patients defined by history of widespread pain for at least three months and pain in 11 of 18 tender point sites on digital palpation. Key exclusion criteria were severe psychiatric illness, current major depressive episode, significant risk of suicide, alcohol or other drug abuse, a history of significant cardiovascular, respiratory, endocrine, genitourinary, liver, or kidney disease, autoimmune disease, systemic infection, cancer or current chemotherapy, significant sleep apnea, active peptic ulcer or inflammatory bowel disease. All centrally acting therapies including antidepressants, sedative-hypnotics, muscle relaxants, benzodiazepines, centrally acting analgesics were stopped during the washout period between 1-4 weeks. However acetaminophen, aspirin, and stable doses of nonsteroidal antiinflammatory agents (NSAID) were allowed. Primary outcome measures were identical in three studies by Clauw et al.,20) Mease et al.,21) and Arnold et al.23) with the same definition of response rate. Those studies had 2 com-
posite outcomes: 1) a 2-measure composite includes a visual analog scale (VAS) and a Patient Global Impression of Change (PGIC) score. 2) A 3-measure composite had the Medical Outcome Study Short-Form 36 (SF-36) Physical Component Summary (PCS) in addition to the 2-measure composite. Response rates accounted for ≥30% pain improvement from baseline on the VAS pain score, a rating of “very much improved” (score=1) or “much improved” (score=2) on the PGIC, and a ≥6-point improvement from baseline in physical function as measured by the SF-36 PCS. Other three studies19,22,24 did not use composite outcome measures but used measures to evaluate the same domain.

3 months trial of Gendreau et al. study revealed different analgesic effect in milnacipran 100 mg BID and 200 mg QD.19) 2-week average daily pain scores (0-20) were collected for the reduction of pain as a primary outcome. In total of 13 pain measure collected, BID milnacipran reached statistical significance for 9 measures compared to none of the measures reached statistical significance for QD milnacipran. Secondary outcome measures assessed were Patient Global Improvement Change (PGIC), Fibromyalgia Impact Questionnaire (FIQ), Medical Outcomes Study Short Form-36 (SF-36), Jenkins sleep scale, and Arizona Sexual Experiences Scale (ASEX). Both BID and QD dosing showed superiority to placebo on PGIC (73% BID, 77% QD, 38% placebo; p= 0.013 for BID vs placebo, p= 0.008 for QD vs placebo). Total FIQ scores, SF-36 scores and ASEX scores were focused on BID milnacipran but did not reach statistical significance in all 3 measures.19)

Clauw et al. performed a large 15 week trial to evaluate the efficacy and tolerability of milnacipran 100 mg (50 mg BID), 200 mg (100 mg BID) versus placebo.20) Fibromyalgia (FM) composite responder rate (3-measure composite) and FM pain composite responder rate (2-measure composite) were the primary outcome evaluated at week 15. Outcomes on secondary measures include time weighted averages calculated for the individual components of the composite responder analysis. Baseline-observation-carried-forward (BOCF) analyses were used to handle missing data for the primary end points. Last-observation-carried-forward (LOCF) and observed-cases (OC) analyses were also conducted for sensitivity of the study. Composite responder rates for both fibromyalgia (BOCF analysis: p= 0.01 for 100 mg/d, p = 0.02 for 200 mg/d) and fibromyalgia pain (BOCF analysis: p = 0.03 for 100 mg/d, 0.004 for 200 mg/d) revealed statistical significance. The time-weighted averages of the weekly palm-based e-diary pain scores and PGIC scores indicated significant differences between both milnacipran doses and placebo (p < 0.001 for both scores). Both doses of milnacipran appeared significant improvements in multiple secondary outcomes including physical functioning, global improvement, and fatigue.20)

Long term study by Mease et al. used same primary outcomes from the previous clinical trial comparing milnacipran 100 mg/d, 200 mg/d with placebo for 6 months.21) At 15 weeks, FM composite responder rates were significantly high in both dosing group compared to placebo (p = 0.017 for 200 mg/d, p = 0.028 for 100 mg/d). FM pain composite responder rates were statistically significant in milnacipran 200 mg/d (p = 0.032), however did not reach statistical significance in milnacipran 100 mg/d as compared to placebo (p = 0.056). At 27 weeks, only 200 mg/d group achieved statistical significance compared to placebo in fibromyalgia pain.21)

Goldenberg et al. study22) is an extension trial from Mease et al. study.21) 87.7% of patients from the lead-study were enrolled in this 6-month extension study. Patients originally receiving 200 mg/d were continued while patients originally on placebo or 100 mg/d were re-randomized to either 100 mg/d or 200 mg/d. Primary parameters were consistent with the lead-in study including VAS 24-hour or 7-day pain recall, PGIC and FIQ total score and Physical Function subscale score. Pain improvement maintained in additional 6 months for patients on milnacipran 200 mg/d. For patients switched from placebo or 100 mg/d from lead-in study to 200 mg/d also represented additional improvements in pain compared to placebo group in the lead-in study (22.8% and 7.1% improvement in pain, respectively). Further improvement in FIQ total score was achieved for both patient groups switched from placebo or 100 mg/d to 200 mg/d. In
terms of PGIC scores, patients on milnacipran 100 mg/d and 200 mg/d showed improvement over placebo. The limitation of this study is that no p values were provided for results and it cannot be directly compared with other clinical trials owing to the methods used to evaluate and present the data.22)

Arnold et al. evaluated efficacy and safety of milnacipran 100 mg/d in patients with fibromyalgia.23) Patient had longer flexible dose escalation period of 4-6 weeks compared to 2-week period from Mease et al. and Clauw et al. studies. Patients intolerant of 100 mg/d of milnacipran were excluded from the study. For primary outcome the 2-measure composite and 3-measure composite responder definitions were used. Patient on milnacipran 100 mg/d showed significant improvement versus placebo assessed using 2- and 3-measure composite responder rates (p < 0.001). The mean pain scores of the patient on milnacipran reached significant reduction compared with the placebo in dose-escalation phase and this improvement maintained throughout the treatment period (p < 0.001). The proportion of patients with PGIC scores ≤ 2 and SF-36 PCS scores with ≥ 6-point improvement from baseline were statistically significantly improved (p < 0.001). Additional secondary outcome measures including SF-36 MCS and FIQ total scores were observed to show significant improvements over placebo group (p < 0.001). Fatigue was measured with Multidimensional Fatigue Inventory (MFI) total score and energy/vitality domain of SF-36 which also showed significant improvement in patients treated with milnacipran. These results are positive findings in contrast to the mixed results of previous trials suggesting the benefit of milnacipran beyond pain relief including improvements in function and quality of life. The limitation existed in this trial is that only the graphical data of results are shown without the actual points values.23)

Another clinical trial was conducted by Branco et al. in 13 European countries for milnacipran 200 mg/d in treatment of fibromyalgia for 17 weeks.24) A stepwise primary efficacy criterion was used to assess its efficacy. Patients with positive results in 2-measure composite response (VAS and PGIC) were added with FIQ score as a third measure. At week 16, 2-measure composite response rate in full analysis set (FAS) was observed achieving significantly greater improvement with milnacipran 200 mg/d compared to placebo (OR 1.90, 95% CI 1.34 to 2.68, p = 0.0003). FIQ scores were also found to be statistically significantly improved compared to placebo (p = 0.009). Other efficacy endpoints including SF-36 scores, MFI scores, Multiple Ability Self-Report Questionnaire (MASQ) total scores have shown significant improvements. The results from this study are coherent with the findings from previous US studies showing the efficacy and safety of milnacipran 200 mg/d in treating fibromyalgia pain and overall function.24)

Throughout the clinical trials, most commonly observed adverse event was nausea accounting for the main reason for study discontinuation.19-24) Nausea have shown to occur more frequently in patients with milnacipran 200 mg/d but resolved after 1-2 weeks of continued therapy.23) Cardiovascular adverse events caused by milnacipran are mild to moderate increases in pulse rates and slight increase in blood pressure.20-24) Therefore baseline assessment of blood pressure and heart rate before starting milnacipran and throughout the treatment should be performed. Other adverse reactions include constipation, dizziness, hot flash, sweating, vomiting, and headaches.19-24)

**CONCLUSION**

Based on 6 clinical trials, milnacipran has been demonstrated to have efficacy in the treatment of fibromyalgia pain and improved various functional measures of patients with fibromyalgia in rather mixed results. Milnacipran was generally well tolerated and the safety profile data has shown consistency with the most common adverse event being nausea. Unfortunately, clinical trials have limitations of limited patient population without comorbid disorders and some study results cannot be directly compared with other studies. Therefore further studies with variable dosages and larger number of general patient populations are needed to support the use of milnacipran in clinical practice. Drug selection for fibromyalgia needs to be individualized for patients on drug characteristics, patient preference, previous
<table>
<thead>
<tr>
<th>Author</th>
<th>Design</th>
<th>Treatment</th>
<th>Primary Outcome Measures</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gendreau (2005)</td>
<td>3 months R, DB, DE, PC</td>
<td>N = 125</td>
<td>Milnacipran 200 mg QD; 100 mg BID Placebo</td>
<td>Reduction in pain (2-week average daily pain score from e-diary morning report)</td>
</tr>
<tr>
<td>Clauw (2008)</td>
<td>15 weeks MC, R, DB, PC</td>
<td>N = 1196</td>
<td>Milnacipran 50 mg BID; 100 mg BID Placebo</td>
<td>1. FM composite responder rate based on 3 domains: (1) VAS pain score improvement (≥30%) (2) PGIC rating (much improved or very much improved) (3) SF-36 PCS (≥6-point improvement) 2. FM pain composite responder rate based on 2 domains of (1) and (2) from above</td>
</tr>
<tr>
<td>Mease (2009)</td>
<td>27 weeks R, DB, PC</td>
<td>N = 888</td>
<td>Milnacipran 50 mg BID; 100 mg BID Placebo</td>
<td>Same as Clauw20)</td>
</tr>
<tr>
<td>Goldenberg (2010)</td>
<td>6 months R, MC, DB, ET from Mease21)</td>
<td>N = 449</td>
<td>Milnacipran 50 mg BID; 100 mg BID Placebo</td>
<td>VAS over the past 24 hours or 7 days, PGIC, FIQ total score</td>
</tr>
<tr>
<td>Arnold (2010)</td>
<td>15 weeks MC, R, DB, PC</td>
<td>N = 1025</td>
<td>Milnacipran 50 mg BID Placebo</td>
<td>Same as Clauw20)</td>
</tr>
<tr>
<td>Branco (2010)</td>
<td>17 weeks R, DB, PC</td>
<td>N = 884</td>
<td>Milnacipran 00 mg BID Placebo</td>
<td>Stepwise measure using 2-measure composite (VAS and PGIC) FIQ total score measured for positive result from above</td>
</tr>
</tbody>
</table>

BOCF = baseline observation carried forward; DB = double-blind; DE = dose escalation; ET = extension trial; FAS = full analysis set; FIQ = Fibromyalgia Impression Questionnaire; GLMM = generalized linear mixed model; LOCF = last observation carried forward; LSM = least square mean; MC = multicenter; OC = observed cases; OR = odd ratio; PC = placebo-controlled; PGIC = Patient Global Impression of Change; SF-36 PCS = Short Form 36 Physical Component Summary; R = randomized; VAS = visual analog scale;
treatments, comorbidities, and cost.

REFERENCES